Seascape Capital Management Has $2.18 Million Stake in Edwards Lifesciences Co. (NYSE:EW)

Seascape Capital Management increased its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 0.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 32,989 shares of the medical research company’s stock after acquiring an additional 174 shares during the quarter. Seascape Capital Management’s holdings in Edwards Lifesciences were worth $2,177,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the business. Empowered Funds LLC lifted its position in Edwards Lifesciences by 151.2% during the first quarter. Empowered Funds LLC now owns 20,123 shares of the medical research company’s stock worth $1,923,000 after acquiring an additional 12,112 shares during the last quarter. SG Americas Securities LLC lifted its holdings in Edwards Lifesciences by 236.4% during the 1st quarter. SG Americas Securities LLC now owns 97,554 shares of the medical research company’s stock worth $9,322,000 after purchasing an additional 68,556 shares during the last quarter. Oppenheimer & Co. Inc. boosted its stake in Edwards Lifesciences by 23.4% in the 1st quarter. Oppenheimer & Co. Inc. now owns 26,253 shares of the medical research company’s stock valued at $2,509,000 after purchasing an additional 4,977 shares during the period. Illinois Municipal Retirement Fund grew its holdings in Edwards Lifesciences by 116.3% in the 1st quarter. Illinois Municipal Retirement Fund now owns 92,023 shares of the medical research company’s stock valued at $8,794,000 after buying an additional 49,484 shares in the last quarter. Finally, Forsta AP Fonden increased its position in Edwards Lifesciences by 9.4% during the 1st quarter. Forsta AP Fonden now owns 146,100 shares of the medical research company’s stock worth $13,961,000 after buying an additional 12,600 shares during the period. Institutional investors own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Robert W. Baird reduced their target price on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. StockNews.com lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Thursday, July 25th. Evercore ISI lowered their target price on shares of Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating on the stock in a report on Tuesday, October 1st. Bank of America cut Edwards Lifesciences from a “buy” rating to a “neutral” rating and cut their price target for the company from $105.00 to $75.00 in a research note on Thursday, July 25th. Finally, Daiwa America lowered Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 30th. Seventeen investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat, Edwards Lifesciences presently has an average rating of “Hold” and an average price target of $75.67.

Edwards Lifesciences Stock Performance

NYSE EW opened at $66.22 on Friday. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The stock has a market cap of $39.89 billion, a PE ratio of 9.56, a PEG ratio of 3.74 and a beta of 1.12. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.87 and a current ratio of 3.71. The firm’s fifty day moving average price is $67.59 and its two-hundred day moving average price is $76.96.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.67. The business had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a return on equity of 22.56% and a net margin of 70.82%. Edwards Lifesciences’s quarterly revenue was up 8.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.59 EPS. On average, equities analysts expect that Edwards Lifesciences Co. will post 2.57 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Larry L. Wood sold 25,000 shares of the stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the sale, the insider now directly owns 198,526 shares in the company, valued at $13,084,848.66. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total value of $330,400.00. Following the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,101,530.88. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Larry L. Wood sold 25,000 shares of Edwards Lifesciences stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the transaction, the insider now directly owns 198,526 shares of the company’s stock, valued at $13,084,848.66. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 41,250 shares of company stock worth $2,746,988 in the last ninety days. Company insiders own 1.27% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.